TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10078675

Group type: EXPERIMENTAL
Intervention: Midazolam 1.0 mg intravenously and 2.0 mg intravenously
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diazepam emulsion 2.0 mg intravenously and 5.0 mg intravenously
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline 2.0 ml intravenously
Number of subjects: 90
Study: 7677415

Group type: EXPERIMENTAL
Intervention: Acellular vaccines
Number of subjects: 51

Group type: COMPARATOR
Intervention: Whole cell vaccine
Number of subjects: 51
Study: 2187453

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (Cy-A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7216144

Group type: EXPERIMENTAL
Intervention: 1 mg FK 33‐824 i.m. after saline i.v.
Number of subjects: 12

Group type: COMPARATOR
Intervention: 4 mg naloxone i.v. followed by 1 mg FK 33‐824 i.m.
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10 mg naloxone i.v. followed by 1 mg FK 33‐824 i.m.
Number of subjects: 12

Group type: COMPARATOR
Intervention: saline i.v. followed by saline i.m.
Number of subjects: 12
Study: 31924197

Group type: EXPERIMENTAL
Intervention: BUD/FORM
Number of subjects: 3576

Group type: COMPARATOR
Intervention: FORM
Number of subjects: 3576
Study: 31102918

Group type: EXPERIMENTAL
Intervention: Genomic risk information intervention
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study: 27567057

Group type: EXPERIMENTAL
Intervention: Intra-Articular Tranexamic Acid (IA TXA)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Intravenous Tranexamic Acid (IV TXA)
Number of subjects: 168
Study: 26015327

Group type: EXPERIMENTAL
Intervention: SOLE
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SuperFeet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Powerstep
Number of subjects: 18

Group type: COMPARATOR
Intervention: No orthotic
Number of subjects: 18
Study: 25109299

Group type: EXPERIMENTAL
Intervention: Augmented Communication‐Output (AC‐O) intervention using speech‐generating devices (SGD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Augmented Communication‐Input (AC‐I) intervention using speech‐generating devices (SGD)
Number of subjects: 0
Study: 22323636

Group type: COMPARATOR
Intervention: Responses in V1, LOC, and hMT+ ROIs with gaps >0.5°
Number of subjects: 0

Group type: COMPARATOR
Intervention: Responses in V4 and V3A ROIs with gaps up to 5.5°
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: V3A ROI sensitivity to disparity noise
Number of subjects: 0
Study: 20196388

Group type: EXPERIMENTAL
Intervention: Oral steroids for Class II patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide 2 mg/kg/d for 12 weeks for Class III patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Azathioprine for 9 months for Classes IV and V patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors for all patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall treatment protocol for severe HSP nephritis
Number of subjects: 18
Study: 17454701

Group type: EXPERIMENTAL
Intervention: Active drug (nortriptyline hydrochloride)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study: 15196296

Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: rizatriptan 5 mg
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg and 5 mg
Number of subjects: 1447
Study: 12189544

Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with women affected by breast cancer
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with unaffected women
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with younger women
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with women with medical and allied health training
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with women in non-professional occupations
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with women with a family history of breast and ovarian cancer
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Consultants' communication behaviours with affected women
Number of subjects: 158
Study: 9694753

Group type: EXPERIMENTAL
Intervention: Amphotericin B in glucose 5%
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Amphotericin B in intralipid 20%
Number of subjects: 51
Study: 8088068

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) starting dose 5 mg/kg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Azathioprine (AZA) starting dose 1.5-2 mg/kg
Number of subjects: 117
Study: 2760256

Group type: EXPERIMENTAL
Intervention: Diltiazem (mean daily dose 360 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nifedipine (mean daily dose 90 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination diltiazem-nifedipine therapy (mean daily dose 55 mg of nifedipine, 360 mg of diltiazem)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 790555

Group type: EXPERIMENTAL
Intervention: Ketoprofen (200 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin (3.6 g daily)
Number of subjects: 30
Study: 31207178

Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Metformin FDC tablet (2.5 mg/500 mg, 7.5 mg/850 mg, or 7.5 mg/1000 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Coadministration of individual components (ertugliflozin with metformin)
Number of subjects: 34
Study: 29713647

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sterile 0.9% saline (Control)
Number of subjects: 37
Study: 26577940

Group type: EXPERIMENTAL
Intervention: FAZA PET imaging
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cisplatin treatment in PET-hypoxic tumors
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tirapazamine treatment in PET-hypoxic tumors
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: FDG PET imaging
Number of subjects: 41
Study: 25115911

Group type: EXPERIMENTAL
Intervention: Low Emission Zones (LEZs)
Number of subjects: 3000000
Study: 22205034

Group type: EXPERIMENTAL
Intervention: Dequalinium chloride (DQC) vaginal tablets
Number of subjects: 321
Study: 19681784

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18412980

Group type: EXPERIMENTAL
Intervention: High-pectin diet (enteral formula: pectin liquid = 2:1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-pectin diet (enteral formula: pectin liquid = 3:1)
Number of subjects: 18
Study: 16029627

Group type: EXPERIMENTAL
Intervention: High-dose IFN alpha-2b 5MIU 6 times per week for 3 - 6 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose IFN alpha-2b 3MIU every other day for 3 - 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 12915606

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 8/4 mg
Number of subjects: 773

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 773
Study: 10452405

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 1833
Study: 8548191

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foscarnet and Ganciclovir
Number of subjects: 0
Study: 1779539

Group type: EXPERIMENTAL
Intervention: Directed transport of antibiotics in autologous blood shadows
Number of subjects: 73

Group type: COMPARATOR
Intervention: Traditional nonoperative treatment
Number of subjects: 73
Study: 7014570

Group type: EXPERIMENTAL
Intervention: Dipyridamole/ASA
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control
Number of subjects: 364
Study: 28398490

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Implantable Cardioverter Defibrillator (ICD)
Number of subjects: 1270
Study: 27593381

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injected (1.5 ml)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal saline injected (1.5 ml)
Number of subjects: 19
Study: 25122597

Group type: EXPERIMENTAL
Intervention: Intratympanic steroid injection
Number of subjects: 31
Study: 22645323

Group type: EXPERIMENTAL
Intervention: Steroid avoidance
Number of subjects: 222

Group type: COMPARATOR
Intervention: Maintenance steroids
Number of subjects: 222
Study: 20380718

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 450
Study: 18940487

Group type: EXPERIMENTAL
Intervention: 1 IA infiltration of sodium hyaluronate (1 mL)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral administration of methocarbamol (380 mg) and paracetamol (300 mg) every 6 hours for 4 weeks
Number of subjects: 41
Study: 17477204

Group type: EXPERIMENTAL
Intervention: Anesthesia instructions - 'think of the hand as numb and insensitive as if it were a piece of rubber...'.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hypnotic induction procedure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Demands for honest reports
Number of subjects: 80
Study: 12585146

Group type: EXPERIMENTAL
Intervention: Yufeng Capsule (YFC)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Venoruton (Control)
Number of subjects: 171
Study: 11147151

Group type: EXPERIMENTAL
Intervention: Closed kinetic chain (CKC) exercises
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Closed kinetic chain (CKC) + open kinetic chain (OKC) exercises
Number of subjects: 44
Study: 9174305

Group type: EXPERIMENTAL
Intervention: IT neostigmine 10, 30, or 100 microg
Number of subjects: 24

Group type: COMPARATOR
Intervention: IT placebo (glucose control)
Number of subjects: 24
Study: 1540431

Group type: EXPERIMENTAL
Intervention: Heparin (5000 units intravenously followed by 1000 units hourly without dose adjustment)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo for heparin
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 652
Study: 3536765

Group type: EXPERIMENTAL
Intervention: RU 41740 (Biostim®) 8 mg daily for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30273569

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 2203

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 2203

Group type: EXPERIMENTAL
Intervention: On-pump and Off-pump CABG
Number of subjects: 2203
Study: 30264918

Group type: EXPERIMENTAL
Intervention: Avatrombopag
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27783545

Group type: EXPERIMENTAL
Intervention: Access to Patient Drug Adherence Information (PDAI)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Access to PDAI
Number of subjects: 219
Study: 25900517

Group type: EXPERIMENTAL
Intervention: FDC (FF 100 μg/LEVO 200 μg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: FF (100 μg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: LEVO (200 μg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 23084100

Group type: EXPERIMENTAL
Intervention: Grafted moderate lesions
Number of subjects: 619

Group type: COMPARATOR
Intervention: Ungrafted moderate lesions
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Left-sided grafts (arterial and vein)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Right-sided grafts
Number of subjects: 619

Group type: COMPARATOR
Intervention: Moderate lesions in the right coronary artery (ungrafted)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Moderate lesions in the left coronary territory (grafted)
Number of subjects: 619
Study: 21042763

Group type: EXPERIMENTAL
Intervention: 45 mg/m2 docetaxel
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 180 mg/m2 irinotecan with 5-FU/leucovorin
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Normal baseline tumour marker levels (except CA72-4)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Baseline tumour marker levels
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Early changes in tumour markers during treatment
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Model combining baseline level, change, and interaction
Number of subjects: 73
Study: 19213350

Group type: EXPERIMENTAL
Intervention: Retention Enema (RE) group
Number of subjects: 93

Group type: COMPARATOR
Intervention: Oral Medicated (OM) group
Number of subjects: 93
Study: 16380568

Group type: EXPERIMENTAL
Intervention: Suicide Risk Screen
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Simpler, more specific screening instrument
Number of subjects: 1323
Study: 14740952

Group type: EXPERIMENTAL
Intervention: Monovalent live attenuated dengue virus vaccine candidates
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Monovalent vaccines (second dose at 30 or 90 days)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine (single dose)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine (second dose at one month)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine (third dose at four months)
Number of subjects: 59
Study: 11167770

Group type: EXPERIMENTAL
Intervention: Endotoxin (2 ng/kg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 8825535

Group type: EXPERIMENTAL
Intervention: Propofol (10 mg iv)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg iv)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg iv)
Number of subjects: 78
Study: 1405290

Group type: EXPERIMENTAL
Intervention: Gidazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethacizin
Number of subjects: 0
Study: 30958356

Group type: EXPERIMENTAL
Intervention: ω3‐FA supplementation (1.7g docosahexaenoic acid and 0.6g eicosapentaenoic acid daily for 6 months)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: ω3‐FA supplementation
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 27870826

Group type: EXPERIMENTAL
Intervention: rhIGF‐1/rhIGFBP‐3, administered at 250 µg/kg/d continuous i.v. infusion up to postmenstrual age 29 wk+6 d
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 19
Study: 26346751

Group type: EXPERIMENTAL
Intervention: Self‐regulated training with exergames played with the Windows Kinect® sensor and FitBit® pedometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional self‐regulated exercise programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (exergames and conventional exercises)
Number of subjects: 0
Study: 23578197

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gin
Number of subjects: 0
Study: 21329027

Group type: COMPARATOR
Intervention: Single Sling (SSling)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Double Sling (DSling)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Rescue Stretcher
Number of subjects: 27

Group type: COMPARATOR
Intervention: Rescue Basket (RB)
Number of subjects: 27
Study: 19895741

Group type: EXPERIMENTAL
Intervention: Ligation group (19 patients)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-ligation group (20 patients)
Number of subjects: 39
Study: 17635423

Group type: EXPERIMENTAL
Intervention: Pre-oxygenation followed by nasopharyngeal oxygen insufflation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pre-oxygenation alone
Number of subjects: 34
Study: 14766685

Group type: EXPERIMENTAL
Intervention: Phonomyography
Number of subjects: 15

Group type: COMPARATOR
Intervention: Balloon pressure mechanomyography
Number of subjects: 15
Study: 12174060

Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate sclerotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Long-pulsed 1064 nm Nd:YAG laser irradiation
Number of subjects: 20
Study: 9848295

Group type: EXPERIMENTAL
Intervention: Discontinuation of luteal phase support in women with serum progesterone levels of > or = 60 ng/mL at 4 weeks' gestation
Number of subjects: 188

Group type: COMPARATOR
Intervention: Continuation of luteal phase support in women with serum progesterone levels of < 60 ng/mL at 4 weeks' gestation
Number of subjects: 188
Study: 7806870

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (18 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (22 patients)
Number of subjects: 40
Study: 2642453

Group type: EXPERIMENTAL
Intervention: Doxorubicin + Cyclophosphamide + BCG (DC + BCG)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Doxorubicin + Cyclophosphamide + Cisplatin (DCP)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Doxorubicin + Cyclophosphamide + Cisplatin + BCG (DCP + BCG)
Number of subjects: 98
Study: 241598

Group type: EXPERIMENTAL
Intervention: Alclofenac
Number of subjects: 35

Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 35
Study: 30710664

Group type: EXPERIMENTAL
Intervention: tPEMF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 26089332

Group type: EXPERIMENTAL
Intervention: Average SBP <144 mm Hg
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Average SBP >157 mm Hg
Number of subjects: 541

Group type: COMPARATOR
Intervention: Average SBP between 144 and 157 mm Hg
Number of subjects: 541
Study: 24725967

Group type: EXPERIMENTAL
Intervention: Peripheral blood gene expression profiling
Number of subjects: 148
Study: 21813090

Group type: EXPERIMENTAL
Intervention: 0.59‐mg fluocinolone acetonide (FA) implant
Number of subjects: 196
Study: 18692420

Group type: EXPERIMENTAL
Intervention: Behaviour Graded Activity (BGA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Exercise (CE)
Number of subjects: 100
Study: 17717236

Group type: EXPERIMENTAL
Intervention: bupivacaine
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: ropivacaine
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: levobupivacaine
Number of subjects: 222
Study: 15258869

Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg intravenous morphine sulfate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11705788

Group type: EXPERIMENTAL
Intervention: OCP (oral contraceptives containing progesterone)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: OCEP (oral contraceptives containing progesterone and estrogen)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 8

Group type: COMPARATOR
Intervention: OCP and OCEP
Number of subjects: 8
Study: 9626922

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 4 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 10
Study: 7829693

Group type: EXPERIMENTAL
Intervention: Ammonium chloride
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral calcium (25 mmol)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chronic hypercalcaemia (primary hyperparathyroidism)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3050188

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX) 20 mg/kg intravenous dose
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX) for prophylaxis
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX) 10 mg/kg intravenous dose
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX) 20 mg/kg one shot dose
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX) in various dosing regimens
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CZX)
Number of subjects: 112
Study: 31782193

Group type: EXPERIMENTAL
Intervention: Nasal Spray (NS)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) kit
Number of subjects: 207

Group type: COMPARATOR
Intervention: Improvised Nasal Atomizer (AT) kit
Number of subjects: 207
Study: 31188825

Group type: EXPERIMENTAL
Intervention: Care management intervention in addition to usual care
Number of subjects: 495

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 495
Study: 27243353

Group type: EXPERIMENTAL
Intervention: 0.3% hyaluronic acid artificial tear (Visaid 0.3%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.9% saline solution (0.9% NaCl)
Number of subjects: 16
Study: 26357896

Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline (HS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 100
Study: 24111258

Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-on-task (TOT) influence on WKL classification
Number of subjects: 0
Study: 21218388

Group type: EXPERIMENTAL
Intervention: Oral antioxidant supplementation at nutritional doses
Number of subjects: 105

Group type: COMPARATOR
Intervention: No antioxidant supplementation (Control)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups (supplementation and control)
Number of subjects: 105
Study: 19335382

Group type: EXPERIMENTAL
Intervention: WHO-Five Well-Being Index (WHO-5-T)
Number of subjects: 300
Study: 17535867

Group type: EXPERIMENTAL
Intervention: Testosterone therapy for 6 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy age-related controls
Number of subjects: 12
Study: 16136168

Group type: EXPERIMENTAL
Intervention: Intensive-timing induction therapy followed by matched related donor allogeneic transplantation
Number of subjects: 1903

Group type: COMPARATOR
Intervention: Standard-timing induction therapy
Number of subjects: 1903
Study: 12115358

Group type: EXPERIMENTAL
Intervention: BRI-based prophylaxis strategy
Number of subjects: 512

Group type: COMPARATOR
Intervention: Platelet threshold strategy of 20,000 per microL
Number of subjects: 512

Group type: COMPARATOR
Intervention: Platelet threshold strategy of 10,000 per microL
Number of subjects: 512